Evidence map›Paper›PMID 37006234›Full record

ArticleFrontiers in immunology2023

Integrated analysis to identify the prognostic and immunotherapeutic roles of coagulation-associated gene signature in clear cell renal cell carcinoma.

Guicao Yin, Tai Tian, Xing Ji, Shengqi Zheng, Zhenpeng Zhu, Yifan Li, Cuijian Zhang

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Guicao YinAffiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, China.
Tai TianDepartment of Urology, Peking University First Hospital, Beijing, China.
Xing JiDepartment of Urology, The Third Affiliated Hospital of Hebei Medical University, Shijiazhuang, China.
Shengqi ZhengAffiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, China.
Zhenpeng ZhuDepartment of Urology, The Third Affiliated Hospital of Hebei Medical University, Shijiazhuang, China.
Yifan LiAffiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, China.
Cuijian ZhangDepartment of Urology, The Third Affiliated Hospital of Hebei Medical University, Shijiazhuang, China.
Yangzhou University · CNThird Hospital of Hebei Medical University · CNHebei Medical University · CNPeking University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The coagulation system is closely related to the physiological status and immune response of the body. Recent years, studies focusing on the association between coagulation system abnormalities and tumor progression have been widely reported. In clear cell renal cell carcinoma (ccRCC), poor prognosis often occurs in patients with venous tumor thrombosis and coagulation system abnormalities, and there is a lack of research in related fields. Significant differences in coagulation function were also demonstrated in our clinical sample of patients with high ccRCC stage or grade. Therefore, in this study, we analyzed the biological functions of coagulation-related genes (CRGs) in ccRCC patients using single-cell sequencing and TCGA data to establish the 5-CRGs based diagnostic signature and predictive signature for ccRCC. Univariate and multivariate Cox analyses suggested that prognostic signature could be an independent risk factor. Meanwhile, we applied CRGs for consistent clustering of ccRCC patients, and the two classes showed significant survival and genotype differences. The differences in individualized treatment between the two different subtypes were revealed by pathway enrichment analysis and immune cell infiltration analysis. In summary, we present the first systematic analysis of the significance of CRGs in the diagnosis, prognosis, and individualized treatment of ccRCC patients.

Indexed as

CarcinomaCarcinoma, Renal CellKidney NeoplasmsBlood CoagulationHumansImmunotherapyPrognosisclear cell renal cell carcinomacoagulation-related genediagnostic signatureindividualized treatmentprognostic signature

Identifiers

PMID37006234
PMCPMC10063824
OpenAlexW4327699264

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.